Content deleted Content added
→Mechanism of action: Added information on the type of patients likely to benefit from PARP inhibitor therapy. |
Filled in 2 bare reference(s) with reFill 2 |
||
Line 42:
* [[Talazoparib]] after trials for advanced hematological malignancies and for advanced or recurrent solid tumors.<ref>{{cite web |author=BioMarin Pharmaceutical Inc. |date=28 July 2011 |title=BioMarin Announces Second Quarter 2011 Financial Results |url=http://www.prnewswire.com/news-releases/biomarin-announces-second-quarter-2011-financial-results-126347308.html |work=prnewswire.com}}</ref> it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer.<ref>{{cite web |date=2013-10-31 |title=BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer. Oct 2013 |url=http://www.benzinga.com/news/13/10/4038789/biomarin-initiates-phase-3-bmn-673-trial-for-metastatic-gbrca-breast-cancer |work=Benzinga}}</ref>
* [[Veliparib]] June 2014 in phase III trials, for advanced ovarian cancer, [[triple-negative breast cancer]] and in [[non-small cell lung cancer]] (NSCLC).<ref name="June2014">{{cite web |date=27 June 2014 |title=AbbVie takes PARP inhibitor into third phase III trial |url=http://www.pmlive.com/pharma_news/abbvie_takes_parp_inhibitor_into_third_phase_iii_trial_581059 |website=PMLive}}</ref>
* [[Pamiparib]] (BGB-290) For ovarian cancer, 1st patient enrolled May 2018.<ref>{{cite press release |title=BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer |date=17 May 2018|url=https://globenewswire.com/news-release/2018/05/17/1508005/0/en/BeiGene-Initiates-Phase-3-Trial-of-Pamiparib-as-Maintenance-Therapy-in-Chinese-Patients-with-Ovarian-Cancer.html}}</ref> It is a PARP1 and PARP2 inhibitor.<ref>
Started Phase II:
| |||